{
    "nct_id": "NCT05726864",
    "official_title": "First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors",
    "inclusion_criteria": "* KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor\n* Phase 1 only: positive for circulating tumor DNA and/or elevated serum tumor biomarkers (such as CA19-9 and CEA) despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable\n* Screening CT is negative for recurrent disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of tumor mutations where specific therapy is approved\n* Known brain metastases\n* Use of immunosuppressive drugs",
    "miscellaneous_criteria": ""
}